CytOSorb TreatMent Of Critically Ill PatientS Registry

Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based resource to measure and improve the quality of patient care

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Septic Shock Acute Liver Failure Acute Respiratory Distress Syndrome Acute on Chronic Liver Failure Acute-On-Chronic Liver Failure Burns Cardiogenic Shock Cardiovascular Diseases Chemically-Induced Disorders Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Cytokine Release Syndrome (CRS) Communicable Diseases Cytokine Release Syndrome Digestive System Diseases Disease Attributes Drug Misuse Drug Overdose Extracorporeal Life Support Heart Diseases Hemic and Lymphatic Diseases Hemophagocytic Lymphohistiocytoses Hepatic Insufficiency Histiocytosis Histiocytosis, Non-Langerhans-Cell Infarction Infections Infectious Disease Inflammation Ischemia Liver Diseases Liver Failure Liver Failure, Acute Liver Transplant; Complications Lung Diseases Lymphatic Diseases Lymphohistiocytosis, Hemophagocytic Mental Disorders Muscular Diseases Musculoskeletal Diseases Myocardial Infarction Myocardial Ischemia Necrosis Pancreatic Diseases Pancreatitis Pathologic Processes Pathological Conditions, Signs and Symptoms Postoperative Complications Postoperative Endocarditis Postoperative Vasoplegic Syndrome Prescription Drug Misuse Respiration Disorders Respiratory Distress Syndrome Respiratory Tract Diseases Rhabdomyolysis Sepsis Shock Shock, Cardiogenic Shock, Septic Substance-Related Disorders Systemic Inflammatory Response Syndrome Trauma Vascular Diseases Vasoplegia Wounds and Injuries

Sex eligibility

All sexes

Study type

Observational

Primary location

Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Planned OR actual CytoSorb® 300 mL device utilization
Informed consent for prospective registry participation

Exclusion criteria

Use of the CytoSorb® 300 mL device for antithrombotic removal only
Intraoperative use of CytoSorb® 300 mL device during cardiac surgery only
The occurrence of a complication or other medically justified circumstance that arises after written informed consent has been obtained from the patient and before or during the planned therapy and as a result of which the use of CytoSorb® 300 mL Adsorber is contraindicated or no longer appropriate.

Treatment and study plan

CytoSorb

Device

Sorbent hemoperfusion system

Primary outcomes

ICU mortality

Time frame: Through ICU discharge or date of death, whichever comes first [on average 7 days]
In-hospital mortality

Time frame: Through hospital discharge or date of death, whichever comes first [on average 14 days]

Study contacts

Contact information is provided by the study sponsor or research team.

Robert Wilke

CONTACT

[email protected]

+49 30 654 99 145

Sponsors and collaborators

Lead sponsor

CytoSorbents, Inc

Industry

Registry information

Official study title

CytOSorb TreatMent Of Critically Ill PatientS Registry: International Registry on the Use of CytoSorb in the Critical Care Setting

Acronym: COSMOS

Important dates

Study start: 2022
Primary completion: 2032
Study completion: 2032
First posted: Dec 6, 2021
Registry last updated: Sep 11, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting